1. Home
  2. BLKB vs VCEL Comparison

BLKB vs VCEL Comparison

Compare BLKB & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackbaud Inc.

BLKB

Blackbaud Inc.

HOLD

Current Price

$37.61

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$33.27

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLKB
VCEL
Founded
1981
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
BLKB
VCEL
Price
$37.61
$33.27
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$50.00
$57.75
AVG Volume (30 Days)
546.8K
508.0K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
142.32
60.00
EPS
0.67
N/A
Revenue
N/A
$276,259,000.00
Revenue This Year
$6.26
$19.40
Revenue Next Year
$4.25
$18.24
P/E Ratio
$56.40
$110.80
Revenue Growth
N/A
16.45
52 Week Low
$33.95
$28.95
52 Week High
$74.86
$45.97

Technical Indicators

Market Signals
Indicator
BLKB
VCEL
Relative Strength Index (RSI) 47.18 44.39
Support Level $34.65 $30.12
Resistance Level $40.38 $34.77
Average True Range (ATR) 2.21 2.16
MACD 0.22 -0.11
Stochastic Oscillator 54.87 16.35

Price Performance

Historical Comparison
BLKB
VCEL

About BLKB Blackbaud Inc.

Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: